Search Results
CASPAR: the addition of rucaparib to enzalutamide for the treatment of mCRPC
Dr. Agarwal on the Safety Profile of Enzalutamide/Talazoparib in mCRPC
Current perspectives from clinical trials using PARP inhibitors for prostate cancer
PARP Inhibitor Combination Regimens for Prostate Cancer Management
PARP inhibitors – a cancer drug discovery story | Professor Ruth Plummer FMedSci
Challenges in the field of PARPi treatment for mCRPC
M2 - Evolving landscape of PARP inhibitors in mCRPC: combination with anti-androgens
Dr. Ledermann on Response to Rucaparib in Recurrent Ovarian Cancer
The evolving treatment landscape of mHSPC and mCRPC
OS after progression on first novel hormonal therapy in mCSPC vs mCRPC
Rucaparib maintenance and monotherapy for ovarian cancer: trial updates
The delivery of niraparib and rucaparib as ovarian cancer treatment options
